Publication:
Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies

dc.contributor.authorRazquin, Cristina
dc.contributor.authorRuiz-Canela, Miguel
dc.contributor.authorClish, Clary B
dc.contributor.authorLi, Jun
dc.contributor.authorToledo, Estefanía
dc.contributor.authorDennis, Courtney
dc.contributor.authorLiang, Liming
dc.contributor.authorSalas-Huetos, Albert
dc.contributor.authorPierce, Kerry A
dc.contributor.authorGuasch-Ferre, Marta
dc.contributor.authorCorella, Dolores
dc.contributor.authorRos, Emilio
dc.contributor.authorEstruch, Ramon
dc.contributor.authorGomez-Gracia, Enrique
dc.contributor.authorFito, Montserrat
dc.contributor.authorLapetra, Jose
dc.contributor.authorRomaguera, Dora
dc.contributor.authorAlonso-Gomez, Angel
dc.contributor.authorSerra-Majem, Lluis
dc.contributor.authorSalas-Salvado, Jordi
dc.contributor.authorHu, Frank B
dc.contributor.authorMartinez-Gonzalez, Miguel A
dc.date.accessioned2024-09-10T13:06:55Z
dc.date.available2024-09-10T13:06:55Z
dc.date.issued2019-11-13
dc.description.abstractBackground: The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special interest. Our aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid (2-AAA) or pipecolic acid with the risk of T2D or CVD in the PREDIMED trial; (b) the effect of the dietary intervention on 1-year changes in these metabolites, and (c) whether the Mediterranean diet (MedDiet) interventions can modify the effects of these metabolites on CVD or T2D risk. Methods: Two unstratified case-cohort studies nested within the PREDIMED trial were used. For CVD analyses, we selected 696 non-cases and 221 incident CVD cases; for T2D, we included 610 non-cases and 243 type 2 diabetes incident cases. Metabolites were quantified using liquid chromatography-tandem mass spectrometry, at baseline and after 1-year of intervention. Results: In weighted Cox regression models, we found that baseline lysine (HR+1 SD increase = 1.26; 95% CI 1.06-1.51) and 2-AAA (HR+1 SD increase = 1.28; 95% CI 1.05-1.55) were both associated with a higher risk of T2D, but not with CVD. A significant interaction (p = 0.032) between baseline lysine and T2D on the risk of CVD was observed: subjects with prevalent T2D and high levels of lysine exhibited the highest risk of CVD. The intervention with MedDiet did not have a significant effect on 1-year changes of the metabolites. Conclusions: Our results provide an independent prospective replication of the association of 2-AAA with future risk of T2D. We show an association of lysine with subsequent CVD risk, which is apparently diabetes-dependent. No evidence of effects of MedDiet intervention on lysine, 2-AAA or pipecolic acid changes was found. Trial registration ISRCTN35739639; registration date: 05/10/2005; recruitment start date 01/10/2003en
dc.description.sponsorshipThis research was supported by the National Institutes of Health HL118264, R01DK102896 and 2R01HL118264; Instituto de Salud Carlos III, Madrid, Spain: RD06/0045, RTIC G03/140, and CIBERobn (CB06/03).es_ES
dc.format.number1es_ES
dc.format.page151es_ES
dc.format.volume18es_ES
dc.identifier.citationRazquin C, Ruiz-Canela M, Clish CB, Li J, Toledo E, Dennis C, et al. Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies. Cardiovasc Diabetol. 2019 Nov 13;18(1):151.en
dc.identifier.doi10.1186/s12933-019-0958-2
dc.identifier.e-issn1475-2840es_ES
dc.identifier.journalCardiovascular Diabetologyes_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/13075
dc.identifier.pubmedID31722714es_ES
dc.identifier.puiL629863561
dc.identifier.scopus2-s2.0-85074961499
dc.identifier.urihttps://hdl.handle.net/20.500.12105/22664
dc.identifier.wos497753100001
dc.language.isoengen
dc.publisherBioMed Central (BMC)
dc.relation.publisherversionhttps://dx.doi.org/10.1186/s12933-019-0958-2en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectBiomarkers
dc.subjectMetabolites
dc.subjectCardiovascular disease
dc.subjectType 2 diabetes
dc.subjectDietary intervention
dc.subject.decsModelos de Riesgos Proporcionales*
dc.subject.meshCardiovascular Diseases*
dc.subject.meshDiabetes Mellitus, Type 2*
dc.titleLysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studiesen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublication4fe896aa-347b-437b-a45b-95f4b60d9fd3
relation.isPublisherOfPublication.latestForDiscovery4fe896aa-347b-437b-a45b-95f4b60d9fd3

Files